LPA1 ANTAGONISTS FOR TREATING INTERSTITIAL LUNG DISEASE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 8, 2024
app pub date -
Dec 22, 2023
filing date -
Dec 23, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
This disclosure relates to methods of treating interstitial lung disease by administering Compound A to the subject at one or more daily dosages lower than the standard daily dosage during a dose titration period of treatment then increasing the dosage to the standard daily dosage of Compound A, wherein the standard daily dosage is about 240 mg/day of Compound A, or an equivalent amount of a pharmaceutically acceptable salt thereof.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully